Related Experiment Videos
Immunochemotherapy (thymostimulin/cyclophosphamide) in dogs.
J A Montoya1, E M Martínez, M Rodríguez
1Dpto. de Patología Animal, Facultad de Veterinaria, Madrid, Spain.
The British Veterinary Journal
|May 1, 1990
Summary
Thymostimulin (TP-1) effectively counteracts chemotherapy-induced immune suppression in dogs. This study shows TP-1 prevents drops in white blood cells and lymphocytes, maintaining immune health during treatment.
Area of Science:
- Veterinary immunology
- Pharmacology
Background:
- Cyclophosphamide chemotherapy can cause significant immunosuppression in dogs.
- Leucolymphopoiesis, the production of white blood cells and lymphocytes, is crucial for immune function.
- Identifying agents to mitigate chemotherapy side effects is vital in veterinary medicine.
Purpose of the Study:
- To evaluate the immunomodulatory effects of thymostimulin (TP-1) in dogs undergoing cyclophosphamide chemotherapy.
- To determine if TP-1 can prevent or reverse chemotherapy-induced leucopenia and lymphopenia.
Main Methods:
- A study involving healthy dogs treated with cyclophosphamide chemotherapy.
- Administration of thymostimulin (TP-1) to the treatment group.
- Comparison with a control group receiving a placebo instead of TP-1.
Main Results:
- Thymostimulin (TP-1) prevented the characteristic drop in leucocyte and lymphocyte counts.
- Dogs treated with TP-1 showed restored leucocyte and lymphocyte levels to pre-treatment values.
- The control group receiving placebo exhibited sustained immune depression throughout chemotherapy cycles.
Conclusions:
- Thymostimulin (TP-1) demonstrates a positive effect on leucolymphopoiesis in dogs.
- TP-1 can effectively counteract chemotherapy-induced immunosuppression.
- This suggests TP-1 as a potential supportive therapy in veterinary oncology.